Search Medical Condition
Please enter condition
Please choose location

Beech Grove, Indiana Clinical Trials

A listing of Beech Grove, Indiana clinical trials actively recruiting patient volunteers.

RESULTS

Found (410) clinical trials

Study of the Effect of a 5-day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Donors

A, multi-center, open-label, single-arm clinical study to assess effects of a 5-day regimen of 10 μg/kg of tbo-filgrastim administered sc daily on the mobilization of CD34+ cells in at least 60 healthy male and female donors. The pharmacokinetics, pharmacodynamics, safety, tolerability, and immunogenicity of tbo-filgrastim will be assessed .

Phase

0.0 miles

Learn More »

Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)

This study will evaluate the safety and tolerability of nilotinib after failure of imatinib therapy or imatinib therapy after nilotinib failure.

Phase

0.0 miles

Learn More »

Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

This is a Phase 2/3, multicenter study of imetelstat that consists of 2 parts. Part 1 is an open‐label, single-arm design to assess the efficacy and safety of imetelstat. Approximately 55 participants will be enrolled in Part 1, including the expansion cohort, and be followed-up for safety, hematologic improvement and ...

Phase

2.58 miles

Learn More »

Randomized On-X Anticoagulation Trial

This is a longitudinal, randomized (randomization to occur at the 3-month follow-up) study comparing the On-X valve on low dose anticoagulation (test group) to concomitant control groups of On-X valves receiving standard Coumadin/aspirin therapy, and also to FDA objective performance criteria (OPC) for heart valve replacement. It is a multicenter ...

Phase N/A

3.08 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

The purpose of this study is to evaluate the efficacy and safety of INCB054828 in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1 rearrangement.

Phase

3.08 miles

Learn More »

Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency

This is a double-blind, multicenter, prospective, randomized, placebo-controlled study to assess the effects of IV FCM compared to placebo on the 12-month rate of death, hospitalization for worsening heart failure, and the 6-month change in 6 minute walk test (6MWT) for patients in heart failure with iron deficiency. After an ...

Phase

3.08 miles

Learn More »

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel Carboplatin and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian Fallopian Tube or Primary Peritoneal Cancer

This is a Phase III, global, double-blind, two-arm, randomized study designed to evaluate the efficacy and safety of atezolizumab administered with paclitaxel + carboplatin + bevacizumab compared with placebo + paclitaxel + carboplatin + bevacizumab in participants with Stage III or Stage IV ovarian (OC), fallopian tube (FTC), or primary ...

Phase

3.08 miles

Learn More »

Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce associated complications in adults with cirrhosis due to NASH.

Phase

3.08 miles

Learn More »

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.

Phase

3.08 miles

Learn More »

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).

Phase

3.08 miles

Learn More »